The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Expression quantitative trait loci (eQTLs) as germline determinants of melanoma immunotherapy response.
 
Robert Ferguson
No Relationships to Disclose
 
Danny Simpson
No Relationships to Disclose
 
Carlos N. Martinez
No Relationships to Disclose
 
Matjaz Vogelsang
No Relationships to Disclose
 
Esther Kazlow
No Relationships to Disclose
 
Una Moran
No Relationships to Disclose
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Celldex; CytomX Therapeutics
Honoraria - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche
Consulting or Advisory Role - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lion Biotechnologies; Merck; Merck; Novartis; Pieris Pharmaceuticals; Roche
 
Ryan J. Sullivan
Consulting or Advisory Role - ACI Clinical; Amgen; Biodesix; Novartis; Prometheus; Takeda; WorldCare Clinical, LLC
Research Funding - Amgen (Inst); BioMed Valley Discoveries (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Roche/Genentech (Inst)
Other Relationship - Boehringer Ingelheim
 
Keith Flaherty
Stock and Other Ownership Interests - Clovis Oncology; Loxo
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Asana Biosciences; Bristol-Myers Squibb; Clovis Oncology; Genentech; Lilly; Loxo; Merck; miRNA Therapeutics; Novartis; Oncoceutics; Roche; Sanofi; Tioma Therapeutics
Research Funding - Novartis; Sanofi
 
Anna C. Pavlick
No Relationships to Disclose
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck; Novartis
 
Iman Osman
No Relationships to Disclose
 
Tomas Kirchhoff
No Relationships to Disclose